{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:10:04Z","timestamp":1773126604966,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.msard.2021.103021","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T01:08:26Z","timestamp":1621386506000},"page":"103021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-5729","authenticated-orcid":false,"given":"Hamza","family":"Coban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Germaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Dimaandal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Haberli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9776-1038","authenticated-orcid":false,"given":"Charanpreet","family":"Padam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina A.","family":"Creed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Imitola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2021.103021_bib0001","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2021.103021_bib0002","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7224\/1537-2073.2016-044","article-title":"Projecting the adequacy of the multiple sclerosis neurologist workforce","volume":"20","author":"Halpern","year":"2018","journal-title":"Int. J. MS. Care"},{"issue":"3","key":"10.1016\/j.msard.2021.103021_bib0003","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2021.103021_bib0004","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2021.103021_bib0005","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and other CD20(+) B-cell-depleting therapies in multiple sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2021.103021_bib0006","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","author":"Hauser","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103021_bib0007","article-title":"Real-world results of ocrelizumab treatment for primary progressive multiple sclerosis","volume":"2020","author":"Daniels","year":"2020","journal-title":"Mult. Scle.r Int."},{"issue":"4","key":"10.1016\/j.msard.2021.103021_bib0008","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000719","article-title":"Ocrelizumab initiation in patients with MS: a multicenter observational study","volume":"7","author":"Ellwardt","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"10.1016\/j.msard.2021.103021_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116973","article-title":"Real world application of ocrelizumab in multiple sclerosis: single-center experience of 128 patients","volume":"415","author":"Prockl","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2021.103021_bib0010","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000431375","article-title":"Clinical expression of multiple sclerosis in hispanic whites of primarily caribbean ancestry","volume":"44","author":"Hadjixenofontos","year":"2015","journal-title":"Neuroepidemiology"},{"issue":"1","key":"10.1016\/j.msard.2021.103021_bib0011","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12883-020-01749-6","article-title":"Multiple sclerosis in a multi-ethnic population from Northern California: a retrospective analysis, 2010-2016","volume":"20","author":"Romanelli","year":"2020","journal-title":"BMC Neurol."},{"issue":"14","key":"10.1016\/j.msard.2021.103021_bib0012","doi-asserted-by":"crossref","first-page":"e1548","DOI":"10.1212\/WNL.0000000000009210","article-title":"Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis","volume":"94","author":"Amezcua","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2021.103021_bib0013","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1047-2797(01)00265-4","article-title":"Racial differences in factors that influence the willingness to participate in medical research studies","volume":"12","author":"Shavers","year":"2002","journal-title":"Ann. Epidemiol."},{"issue":"1","key":"10.1016\/j.msard.2021.103021_bib0014","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ncl.2017.08.007","article-title":"Ethnic considerations and multiple sclerosis disease variability in the United States","volume":"36","author":"Rivas-Rodriguez","year":"2018","journal-title":"Neurol. Clin."},{"issue":"19","key":"10.1016\/j.msard.2021.103021_bib0015","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1212\/WNL.0b013e3182918cc2","article-title":"Incidence of multiple sclerosis in multiple racial and ethnic groups","volume":"80","author":"Langer-Gould","year":"2013","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2021.103021_bib0016","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1474-4422(10)70094-6","article-title":"Multiple sclerosis: risk factors, prodromes, and potential causal pathways","volume":"9","author":"Ramagopalan","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2021.103021_bib0017","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fneur.2018.00174","article-title":"Therapeutic inertia in the new landscape of multiple sclerosis care","volume":"9","author":"Saposnik","year":"2018","journal-title":"Front Neurol."},{"key":"10.1016\/j.msard.2021.103021_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102631","article-title":"Preventive neurology concepts for training the next-generation and closing gaps in real-world multiple sclerosis care","volume":"47","author":"Coban","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103021_bib0019","unstructured":"Prospective Study to Assess Disease activity and biomarkers in minority participants with relapsing multiple sclerosis (RMS) after initiation and during treatment with ocrelizumab. https:\/\/ClinicalTrials.gov\/show\/NCT04377555. Accessed 2020."},{"issue":"1","key":"10.1016\/j.msard.2021.103021_bib0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/03007995.2017.1374937","article-title":"Adherence, persistence, and discontinuation among hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate","volume":"34","author":"Williams","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.msard.2021.103021_bib0021","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40120-020-00193-5","article-title":"Real-world safety and effectiveness of dimethyl fumarate in black or african american patients with multiple sclerosis: 3-year results from ESTEEM","volume":"9","author":"Williams","year":"2020","journal-title":"Neurol. Ther."},{"issue":"4","key":"10.1016\/j.msard.2021.103021_bib0022","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/archneurol.2011.45","article-title":"Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data","volume":"68","author":"Cree","year":"2011","journal-title":"Arch Neurol."},{"issue":"12","key":"10.1016\/j.msard.2021.103021_bib0023","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2021.103021_bib0024","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103021_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102731","article-title":"Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab","volume":"48","author":"Haberli","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103021_bib0026","first-page":"25","article-title":"Emerging cases of severe babesia microti infections in multiple sclerosis patients treated with ocrelizumab: report of two cases","author":"Germaine","year":"2021","journal-title":"ACTRIMS Forum"},{"key":"10.1016\/j.msard.2021.103021_bib0027","unstructured":"Administration USFaD. FDA adverse events reporting system (FAERS) public dashboard. https:\/\/fis.fda.gov\/sense\/app\/d10be6bb-494e-4cd2-82e4-0135608ddc13\/sheet\/6b5a135f-f451-45be-893d-20aaee34e28e\/state\/analysis. Published 2020. Updated March 31, 2020. Accessed July 10, 2020."},{"issue":"4","key":"10.1016\/j.msard.2021.103021_bib0028","doi-asserted-by":"crossref","first-page":"ofx204","DOI":"10.1093\/ofid\/ofx204","article-title":"Two cases of severe tick-borne encephalitis in rituximab-treated patients in germany: implications for diagnosis and prevention","volume":"4","author":"Steininger","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.msard.2021.103021_bib0029","article-title":"Adverse event profile differences between rituximab and ocrelizumab: findings from the FDA adverse event reporting database","author":"Caldito","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103021_bib0030","article-title":"Two cases of meningitis associated with ocrelizumab therapy","volume":"38","author":"Theriault","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2021.103021_bib0031","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1086\/345746","article-title":"Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment","volume":"36","author":"Quartier","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.msard.2021.103021_bib0032","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin. Hematol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:56:33Z","timestamp":1761900993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821002881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":32,"alternative-id":["S2211034821002881"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103021","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103021"}}